Skip to main content
Log in

Pharmacokinetics of ceftazidime in patients with biliary tract disease

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

After administration of ceftazidime as a 1 g i.v. bolus injection, its concentration was measured by HPLC at frequent intervals in serum, bile and tissue from different parts of the biliary tract in 32 patients undergoing operation for biliary tract disease. In bile from the functioning gallbladder and common bile duct, a high concentration of ceftazidime was found, mean 18.5 and 26.6 mg/l, respectively. In bile from the non-functioning gallbladder, a very low concentration was found (<1.5 mg/l). Ceftazidime in the gallbladder wall varied considerably with the type and degree of inflammation judged histologically; the mean level was 21.3 mg/kg. The elimination half-life of ceftazidime was 1.74 h, apparent volume of distribution 20.01 and total plasma clearance 133 ml/min. In bile from T-tube specimens a high concentration was found, the mean peak values being 27.2 mg/l. However, biliary excretion of the drug was low at less than 0.5% of the administered dose. These concentrations of ceftazidime were sufficient to inhibit the in-vitro growth of pathogens, namely theEnterobacteriaecae commonly responsible for biliary tract infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Ayrton J (1981) Assay of ceftazidime in biological fluids using high-pressure liquid chromatography. J Antimicrob Chemother 8 [Suppl B]: 227–331

    Google Scholar 

  • Barza M (1982) Pharmacokinetics of antibiotics. In Sabath LD (ed) Action of antibiotics in patients. Hans Huber, Bern, pp 11–39

    Google Scholar 

  • Cars O, Øgren S (1985) Antibiotic tissue concentrations: Methodological aspects and interpretation of results. Scand J Infect Dis 44 [Suppl]: 7–15

    Google Scholar 

  • Dawson AM (1981) Infections of the extra-hepatic biliary apparatus. In: Smith R, Sherlock S (eds) Surgery of the gallbladder and bile ducts, 2nd edn Butterworth, London, pp 213–224

    Google Scholar 

  • Edlund Y, Mollstedt BO, Ouchterlony O (1959) Bacteriological investigation of the biliary system and liver in biliary tract disease correlated to clinical data and microstructure of the gallbladder and liver. Acta Chirurg Scand 116: 461–476

    Google Scholar 

  • Harding SM, Munro AJ, Thornton JE, Ayrton J, Hogg MIJ (1981) The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. J Antimicrob Chemother 8 [Suppl B] 263–272

    Google Scholar 

  • Harper PB (1981) The in-vitro properties of ceftazidime. J Antimicrob Chemother 8 [Suppl B]: 5–13

    Google Scholar 

  • Jones RN, Barry AL, Thornsberry C, Gerlach EH, Fuchs PC, Gavan TL, Sommers HM (1981) Ceftazidime, a pseudomonasactive cephalosporin: In-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. J Antimicrob Chemother 8 [Suppl B]: 187–211

    Google Scholar 

  • Keighley MRB, Drysdale RB, Quoraismi AH, Burdon DW, Alexander-Williams J (1975) Antibiotic treatment of biliary sepsis: Surg Clin North Am 55: 1397–1390

    Google Scholar 

  • Phillips I, Warren C, Shannon K, King A, Hanslo D (1981) Ceftazidime: In-vitro antibacterial activity and susceptibility to β-lactamases compared to that of cefotaxime, moxalactam and other β-lactam antibiotics. J Antimicrob Chemother 8 [Suppl B]: 23–31

    Google Scholar 

  • Ratzan KR (1984) Bilary tract. In: Ristuccia AM, Cunha BA (eds) Antimicrobial therapy. Raven Press, New York, pp 455–465

    Google Scholar 

  • Rowland M, Tozer ThN (1980) Clinical pharmacokinetics. Consepts and applications. Lea & Febiger, Philadelphia, pp 9–76

    Google Scholar 

  • Ryan DM, Hodges Brenda, Spencer GR, Harding SM (1982) Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid. Antimicrob Agents Chemother 6: 995–998

    Google Scholar 

  • Thomas M (1983) Leading article: Antibiotics in bile. J Antimicrob Chemother 12: 419–422

    Google Scholar 

  • Schoengut H, Jelinek R (1983) Comparative study of the effects of ceftazidime compared with tobramycine plus cefamandole in the treatment of gall bladder empyema. J Antimicrob Chemother 12 [Suppl A]: 219–222

    Google Scholar 

  • Walstad RA, Hellum KB, Svarva PL, Ingram PM (1983a) The evaluation of ceftazidime in the treatment of bacterial infections in eighty seriously ill patients. J Antimicrob Chemother 12 [Suppl A]: 131–137

    Google Scholar 

  • Walstad RA, Hellum KB, Blika S, Dale LG, Fredriksen T, Myhre KI, Spencer GR (1983b) Pharmacokinetics and tissue penetration of ceftazidime: Studies on lymph, aqueous humour, skin blisters, cerebrospinal and pleural fluid. J Antimicrob Chemother 12 [Suppl A]: 275–282

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walstad, R.A., Wiig, J.N., Thurmann-Nielsen, E. et al. Pharmacokinetics of ceftazidime in patients with biliary tract disease. Eur J Clin Pharmacol 31, 327–331 (1986). https://doi.org/10.1007/BF00981132

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00981132

Key words

Navigation